ISG Provider Lens® Life Sciences Digital Services - Clinical Development (Service Providers) - Global 2026

AI and platform ecosystems are driving unified transformation across the life sciences value chain

This study shows the life sciences services landscape progressing beyond function-specific transformation toward value-chain-wide modernization, with IT service providers and CROs both repositioning around integrated, AI-enabled and platform-led delivery. Across clinical development, patient engagement, pharmacovigilance, regulatory functions for CROs, and manufacturing, supply chain and commercial operations for service providers, the shift is moving from isolated digital interventions to connected operating models that integrate data, workflows, compliance and outcomes.

A defining pattern across the market is the transition from digital enablement to intelligence-led execution. GenAI is being embedded into protocol design, documentation, safety processing, engagement orchestration and commercial decision support, while agentic models are beginning to reshape how decisions, content and workflows are coordinated across the life sciences value chain. Rather than functioning as a standalone innovation layer, AI is increasingly being treated as the operating fabric enabling speed, quality, compliance and personalization.

Rising operational complexity and reduced tolerance for fragmented execution are shaping current market dynamics. Clinical and safety environments face demanding regulatory expectations, higher reporting volumes, growing inspection pressure and the need to align interconnected processes across development, regulatory and postapproval functions. Meanwhile, data estates remain distributed across clinical, quality, safety, engagement and enterprise platforms, making interoperability and unified governance essential to achieving transformation success.

A structural shift toward cloud-native, interoperable and platform-centric architectures is accelerating. Unified data foundations, API-led integration, microservices and connected ecosystems spanning clinical, safety, regulatory, engagement and enterprise platforms are emerging as the backbone of scalable modernization. This reflects a broader need for longitudinal visibility, cross-functional intelligence and regulatory-grade traceability throughout the product lifecycle.

Another major shift is the acceleration of decentralized and hybrid models. Clinical development and patient engagement are moving toward lower-friction, more distributed participation models supported by digital tools, remote interactions and real-world data integration. This is expanding the role of technology from workflow support to experience orchestration, with patientcentricity now directly linked to enrollment, retention, adherence and data continuity.

Within this context, CROs are evolving from execution-focused delivery partners to technology-enabled strategic actors. Clinical execution, patient engagement and safety operations are increasingly evaluated together, and differentiation is shifting toward the ability to combine hybrid trial infrastructure, AIenabled workflows, integrated governance and predictable delivery.

Enterprise buyers are prioritizing end-to-end data integration, governance and execution visibility over point solutions. Across the value chain, the emphasis is on connected data environments that support faster decisions, stronger auditability and better workflow coordination. In clinical development, this requires interoperable ecosystems spanning study design, trial management, data capture and regulatory documentation. In patient engagement, it requires unified patient views across multiple interaction channels. In pharmacovigilance and regulatory functions, it demands harmonized environments linking safety, regulatory, clinical and quality systems.

Enterprises are also investing in AI, GenAI and automation as foundational levers of operational performance. Key priorities include accelerating protocol design, improving site selection, automating data mapping, detecting anomalies, enabling AI-assisted documentation, strengthening signal detection, personalizing engagement, improving adherence, supporting intelligent case processing and orchestrating next-best actions. The expectation is that AI will simultaneously reduce cycle times, improve decision quality and strengthen compliance.

Expectations differ across partner types. Service providers are expected to drive enterprise-level transformation and business layers combining platform engineering, cloud modernization, data foundations, commercial enablement and manufacturing digitization. CROs are expected to deliver differentiated value where operational depth intersects with digital execution, particularly in clinical delivery, patient engagement, pharmacovigilance operations and flexible sourcing models.

GenAI and agentic AI adoption priorities also vary by function. Clinical development focuses on protocol optimization, feasibility and intelligent documentation. Patient engagement emphasizes hyper-personalized journeys and conversational interfaces. Pharmacovigilance and regulatory functions prioritize automation, signal detection and structured authoring. Commercial operations focus on decision intelligence and content generation, while manufacturing and supply chain functions emphasize predictive and real-time operational insights.

The ecosystem is evolving through a mix of convergence and differentiation. Service providers are expanding their role through platform engineering, AI enablement, consulting-led transformation and managed services spanning commercial operations, manufacturing, supply chain and enterprise IT layers. Their strength lies in integrating front-, middle- and back-office systems into cohesive, scalable architectures.

CROs are advancing deeper into technologyenabled delivery within the regulated core of the value chain. They are embedding AI, analytics and digital platforms into clinical operations, patient engagement and pharmacovigilance processes to enhance execution quality, speed and predictability. Their evolution centers on combining operational depth with digital acceleration.

Convergence is most visible in clinical data ecosystems, patient engagement and AI-driven orchestration. Both service providers and CROs are building capabilities around interoperable data platforms, workflow automation, predictive analytics and patient-centric models. Success in these areas depends on embedding intelligence directly into operational workflows.

Despite convergence, structural differentiation persists. CROs retain strengths in clinical execution, patient access, pharmacovigilance operations and flexible delivery models. Service providers maintain advantages in enterprisescale transformation, including commercial platforms, manufacturing modernization, cloud infrastructure and cross-functional integration. The result is a complementary yet increasingly overlapping competitive landscape.

Ecosystem-led strategies are becoming more critical. Partnerships, co-innovation models and platform ecosystems play a key role in delivering integrated solutions that combine domain expertise, data interoperability and AI capabilities across the value chain.

The market is entering a new phase defined by progression from GenAI-enabled productivity to agentic coordination and, ultimately, more autonomous operations. Competitive advantage will increasingly depend on the ability to embed intelligence across end-toend workflows spanning clinical development, patient engagement, pharmacovigilance, manufacturing and commercial functions.

Platformization will continue to intensify as unified data environments and interoperable architectures become essential for scaling AI in regulated environments. As a result, boundaries between service providers and CROs will continue to blur, particularly in clinical, patient and regulatory domains where data, execution and compliance intersect.

Future competitive shifts will be driven by the ability to combine regulatory-grade trust, connected data foundations, AInative workflows and measurable business impact. The market will increasingly reward organizations that can translate value-chain complexity into integrated, intelligent and scalable operating models.

Access to the full report requires a subscription to ISG Research. Please contact us for subscription inquiries.